Full notification file
General informationNotification NumberB/NL/15/008Member State to which the notification was sentNetherlandsDate of acknowledgement from the Member State Competent Authority13/05/2015Title of the ProjectThe AGM0001Study: A phase 3 double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of AGM0001 in subjects with critical limb ischemia.Proposed period of release:01/09/2015 to 01/11/2019Name of the Institute(s) or Company(ies)Academisch Ziekenhuis Maastricht, P. Debeijelaan 25
6229 HX Maastricht
The Netherlands;
3. Is the same GMO release planned elsewhere in the Community?NoHas the same GMO been notified elsewhere by the same notifier?NoGMO characterizationGMO is a:Other: The medicinal product is not a GMO per seIdentity of the GMO:Not relevant. The plasmid DNA does not have a taxonomic classification.Information relating to the recipient or parental organisms from wich the GMO is derived| Common Name | Genus | Species | Subspecies | Strain | Pathovar | | pVAX1 | - | - | - | - | - |
|
European Commission administrative informationConsent given by the Member State Competent Authority:Not known